Sept 29 (Reuters) – HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.
ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca.
(Reporting by Roshan Thomas in Bengaluru; Editing by Subhranshu Sahu)
Comments